ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2009
New agents and techniques for imaging prostate cancer.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Early dynamic imaging inEuropean journal of nuclear medicine and molecular imaging · 2017Article
- Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET.Current oncology reports · 2015Review
- New prospects for PET in prostate cancer imaging: a physicist's viewpoint.EJNMMI physics · 2014Article
- Improving PET spatial resolution and detectability for prostate cancer imaging.Physics in medicine and biology · 2014Article
- Pilot study of a novel (18)F-labeled FSHR probe for tumor imaging.Molecular imaging and biology · 2014Article
- Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2014Article
- Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer.Translational andrology and urology · 2013Article
- A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.EJNMMI research · 2012Article
- Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.Current medicinal chemistry · 2012Review
- 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Management of low (favourable)-risk prostate cancer.BJU international · 2011Review
- Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family.Journal of neurochemistry · 2011Review
- Intravital imaging of human prostate cancer using viral nanoparticles targeted to gastrin-releasing Peptide receptors.Small (Weinheim an der Bergstrasse, Germany) · 2011Article
- High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S).Molecular cancer therapeutics · 2011Article
- The evolution of imaging in cancer: current state and future challenges.Seminars in oncology · 2011Review
- An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors.European journal of nuclear medicine and molecular imaging · 2010Article
- Prostate cancer-targeted imaging using magnetofluorescent polymeric nanoparticles functionalized with bombesin.Pharmaceutical research · 2010Article
- The Mind: Focal Cryotherapy in Low-Risk Prostate Cancer: Are We Treating the Cancer or the Mind?International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The successful management of prostate cancer requires early detection, appropriate risk assessment, and optimum treatment. An unmet goal of prostate cancer imaging is to differentiate indolent from aggressive tumors, as treatment may vary for different grades of the disease. Different modalities have been tested to diagnose, stage, and monitor prostate cancer during therapy. This review briefly describes the key clinical issues in prostate cancer imaging and therapy and summarizes the various new imaging modalities and agents in use and on the horizon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.